BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 27
• 28
• 29
• 30

• FDA

  LifeCodexx AG Receives CE Mark For Its Novel NIPT Solution Based On Methylation-Specific Quantitative PCR

  December 7, 2016

   · 

  2 min read
• Business

  Medtronic And Fitbit Partner To Integrate Health And Activity Data Into New CGM Solution For Simplified Type 2 Diabetes Management

  December 7, 2016

   · 

  6 min read
• Drug Development

  TRANSGENE, UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC)

  December 7, 2016

   · 

  6 min read
• BioMidwest

  Integrated DNA Technologies Sustainability Award Supports Biodiversity Research For Second Year

  December 7, 2016

   · 

  4 min read
• Drug Development

  Ariad’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study

  December 7, 2016

   · 

  10 min read
• Biotech Bay

  Invitae Adds Two Genes, Offers Faster Turnaround Time For Its Breast Cancer STAT Panel

  December 7, 2016

   · 

  5 min read
• Business

  Sobi And Horizon Pharma Enter Five-Year Distribution Agreement For Ravicti And Ammonaps Outside The United States

  December 7, 2016

   · 

  10 min read
• Deals

  AddLife Acquires Biolin Scientific AB – World Leading Instruments For Material Analysis At The Nanoscale

  December 7, 2016

   · 

  2 min read
• Biotech Bay

  OptraSCAN Announces CLOUDPath LIMS As Part Of Its On-Demand Digital Pathology Solutions Suite On The Salesforce Appexchange, The World’s Leading Enterprise Apps Marketplace

  December 7, 2016

   · 

  3 min read
• Drug Development

  Merck & Co. Release: KEYTRUDA (Pembrolizumab) Demonstrated Improved Health-Related Quality Of Life Compared To Chemotherapy In First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

  December 7, 2016

   · 

  14 min read